Stock Locations

New Jersey, USA
Czech Republic, EU
Mumbai, India

* Stock subject to availability.

Documentation

Download MSDS

Download Sample COA

Includes: HPLC, MASS/LC-MS, 1H NMR, FT-IR, Potency, Structure Elucidation Report (SER), and additional analytical data depending on the product.

N-Nitroso N-Desmethyl Mifepristone

● Under Development

Catalogue No.:	VE0014195
CAS No.:	N/A
Mol. Formula:	C28H32N2O3
Mol. Weight:	444.6 g/mol

How can we help?

Add to RFQ list

Additional information on N-Nitroso N-Desmethyl Mifepristone

FDA Potency Category 2 NDSRI

100 ng/day is the U.S. FDA’s current Acceptable Intake (AI) limit for N-nitroso-desmethyl-mifepristone (NDSRI). Refer to the FDA nitrosamine page for the latest guidance.

Parent drug

Mifepristone

IUPAC Name

N-(4-((8S, 11R, 13S, 14S, 17S)-17-Hydroxy-13-methyl-3-oxo-17-(prop-1-yn-1-yl)-2, 3, 6, 7, 8, 11, 12, 13, 14, 15, 16, 17-dodecahydro-1H-cyclopenta[a]phenanthren-11-yl)phenyl)-N-methylnitrous amide

Pharmacopoeial Synonyms

N/A

Other Synonyms

N/A

Smiles

O=NN(C1=CC=C([C@H]2C[C@]3(C)[C@@](C#CC)(O)CC[C@@]3([H])[C@]4([H])CCC5=CC(CCC5=C24)=O)C=C1)C

InChI

InChI=1S/C28H32N2O3/c1-4-14-28(32)15-13-25-23-11-7-19-16-21(31)10-12-22(19)26(23)24(17-27(25,28)2)18-5-8-20(9-6-18)30(3)29-33/h5-6,8-9,16,23-25,32H,7,10-13,15,17H2,1-3H3/t23-,24+,25-,27-,28-/m0/s1

Description

N-Nitroso N-Desmethyl Mifepristone is an N-nitroso derivative of the secondary amine present in Mifepristone | which is a highly characterized reference material that meets stringent regulatory standards set for nitrosamine compounds | including those set by USP | EMA | JP | and BP. This nitroso standard is essential for a variety of applications | such as analytical method development | method validation (AMV) | and Quality Control (QC) | particularly in the context of Mifepristone production. It is suitable for use in both Abbreviated New Drug Applications (ANDA) and New Drug Applications (NDA). This nitrosamine standard helps establish detection limits | quantify impurity levels | and ensure trace nitroso impurities in pharmaceutical products remain within FDA and EMA safety limits.